Also, for neurodegenerative dementias, including Alzheimer’s disease (AD) and frontotemporal dementia (FTD), higher levels of blood NfL are informative biomarkers to separate dementia from controls on a group level [10–18]. This evidence concerns the gene NEFL and Alzheimer disease.